Even though therapeutic strategy targeting TIGIT has provided evidence of encouraging efficacy in hematological malignancies, the immune-related adverse events (irAEs) mediated by over-activated T cells may result in multiple organ dysfunction and poor prognosis. This evidence concerns the gene TIGIT and hematologic disorder.